Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:57 AM UTC

Segments 13-16 describe Moderna's successful Phase 3 trial for its personalized cancer vaccine, showing improved outcomes versus Keytruda alone and a 177% stock surge. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:52 AM UTC

Segments 12-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:47 AM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer returning or spreading. Moderna shares closed 177% higher, their largest one-day gain on record. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:42 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:37 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a material positive catalyst that drove a 177% share increase, supporting a BUY operation.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:32 AM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a major clinical milestone that drove a 177% stock surge. This represents a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:27 AM UTC

Segments 12-15 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, the first large late-stage study of a custom cancer therapy using mRNA technology. Patients receiving the treatment with Keytruda went longer without cancer recurrence than those on Keytruda alone, and Moderna shares closed 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:22 AM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a strong positive catalyst.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:17 AM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence, and Moderna shares closing 177% higher. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 04:12 AM UTC

Segments 13-17 describe Moderna's successful Phase 3 trial for its personalized cancer vaccine, showing that patients receiving the treatment with Keytruda had longer progression-free survival than those on Keytruda alone. This is a material positive catalyst for Moderna, supporting a BUY operation.